Bevacizumab With Chemotherapy: — Which Combinations and Why

Usually yes, though the order matters. Bevacizumab is given first as an intravenous infusion; the duration varies by session and your tolerance of earlier doses — initial infusions take longer because your team monitors for reactions, and later ones can be shorter. The chemotherapy follows in the same visit. Some regimens, particularly those including infusional fluorouracil, involve a portable pump you take home for a day or two after your clinic visit. Your team will tell you what your specific session involves and how long to expect to be in the unit.

Bevacizumab carries a serious risk of pulmonary haemorrhage — bleeding from the airways — and this risk is substantially higher in squamous cell lung cancer than in non-squamous types. NCCN guidelines specifically exclude squamous histology from the bevacizumab-containing regimens for this reason. If you have squamous cell lung cancer, your oncologist will recommend a different regimen that does not include bevacizumab. This is not a treatment shortfall — it is the evidence guiding which regimen is safest for your specific cancer type.

Bevacizumab adds its own set of effects rather than amplifying the chemotherapy ones. The most common bevacizumab-specific effects are high blood pressure, protein in the urine, and slower wound healing. Fatigue, nausea, and hair changes come mainly from the chemotherapy partner. Knowing which effect comes from which drug helps you report symptoms accurately, and it helps your team decide which part of the regimen to look at if something changes.

High blood pressure is one of the more common effects of bevacizumab, and it is also one of the most manageable. Your team will measure your blood pressure before every dose. If it rises significantly, they may prescribe blood pressure medication, adjust the bevacizumab dose, or briefly pause it. It rarely means stopping the regimen permanently. Tell your team immediately if you develop a severe headache or visual disturbance between cycles — these can be signs of a significant blood pressure spike that needs prompt review, not a wait-and-see.

This depends on your cancer type, your response to treatment, and your tolerance of side effects. Some regimens run for a fixed number of cycles; others continue as long as the treatment is working and side effects remain manageable. In some cancer types, bevacizumab is continued alone as maintenance therapy after the chemotherapy course is complete — this is seen in certain colorectal and ovarian cancer regimens. Your oncologist will explain the plan for your specific regimen at the start of treatment and will review it at each response scan.

Bevacizumab slows wound healing and increases bleeding risk, so planned surgery is normally postponed until a sufficient interval has passed since your last dose. NCCN guidance recommends a minimum gap before and after any elective surgical procedure, and the exact timing is agreed between your surgical and oncology teams together. If you are injured or need emergency surgery, tell the treating team immediately that you are receiving bevacizumab — it changes how they will manage your care and recovery.